The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6590-6597

  Terme, Magali ^a,b,c   Mignot, Grégoire ^a,c   Ullrich, Evelyn ^a,c   Bonmort, Mathieu ^a,c   Minard Colin, Véronique ^d   Jacquet, Alexandra ^e   Schultze, Joachim L ^f   Kroemer, Guido ^a,b,c   Leclerc, Claude ^a,g   Chaput, Nathalie ^a,b,e   Zitvogel, Laurence ^a,b,c,e  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e IGR   (France)

^f UNIVERSITY OF BONN   (Germany)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD11B ANTIGEN; CD86 ANTIGEN; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERTUSSIS TOXIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CROSS PRESENTATION; CROSS REACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD11B; ANTIGENS, CD86; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERONS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS; TH1 CELLS;

EID: 69249159848     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4473     Document Type: Article

References (32)

1. Bonmort M, Dalod M, Mignot G, Ullrich E, Chaput N, Zitvogel L. Killer dendritic cells: IKDC and the others. Curr Opin Immunol 2008;20:558-65.
2. Wesa AK, Storkus WJ. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ 2008;15:51-7.
3. Trinite B, Voisine C, Yagita H, Josien R. A subset of cytolytic dendritic cells in rat. J Immunol 2000;165:4202-8.
4. Josien R, Heslan M, Soulillou JP, Cuturi MC. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J Exp Med 1997;186:467-72.
5. Schmitz M, Zhao S, Deuse Y, et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 2005;174:4127-34.
6. Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 2002;168:1823-30.
7. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α(1)β(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002;168:1831-9.
8. Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006;12:207-13.
9. Ullrich E, Bonmort M, Mignot G, et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008;180:7887-97.
10. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12:214-9.
11. Vosshenrich CA, Lesjean-Pottier S, Hasan M, et al. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 2007;204: 2569-78.
12. Mignot G, Ullrich E, Bonmort M, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008; 180:6477-83.
13. Caminschi I, Ahmet F, Heger K, et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med 2007; 204:2579-90.
14. Blasius AL, Barchet W, Cella M, Colonna M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med 2007;204: 2561-8.
15. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17:211-20.
16. Kuwano Y, Prazma CM, Yazawa N, et al. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int Immunol 2007;19:977-92.
17. Chaput N, Schartz NE, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004;172: 2137-46.
18. Bonmort M, Ullrich E, Mignot G, Jacobs B, Chaput N, Zitvogel L. Interferon-γ is produced by another player of innate immune responses: the interferonproducing killer dendritic cell (IKDC). Biochimie 2007; 89:872-7.
19. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
20. Pletneva M, Fan H, Park J-J, et al. IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res 2009;69: 6607-14.
21. Fujimoto Y, Tu L, Miller AS, et al. CD83 expression influences CD4+ T cell development in the thymus. Cell 2002;108:755-67.
22. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007; 316:612-6.
23. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cellassociated antigen for cross-presentation. J Immunol 2006;176:6770-6.
24. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
25. Guermonprez P, Khelef N, Blouin E, et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the α(M)β(2) integrin (CD11b/CD18). J Exp Med 2001;193:1035-44.
26. Guermonprez P, Fayolle C, Rojas MJ, Rescigno M, Ladant D, Leclerc C. In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c + CD8 α-CD11bhigh dendritic cells. Eur J Immunol 2002;32: 3071-81.
27. Guermonprez P, Ladant D, Karimova G, Ullmann A, Leclerc C. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J Immunol 1999;162:1910-6.
28. Schlecht G, Loucka J, Najar H, Sebo P, Leclerc C. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J Immunol 2004;173:6089-97.
29. Fayolle C, Ladant D, Karimova G, Ullmann A, Leclerc C. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol 1999;162:4157-62.
30. Welner RS, Pelayo R, Garrett KP, et al. Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors. Blood 2007;109:4825-931.
31. McGreal EP, Miller JL, Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol 2005;17:18-24.
32. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med 1990;172:1785-94.